Right dose, right now: using big data to optimize antibiotic dosing in the critically ill.

Antibiotics save lives and are essential for the practice of intensive care medicine. Adequate antibiotic treatment is closely related to outcome. However this is challenging in the critically ill, as their pharmacokinetic profile is markedly altered. Therefore, it is surprising that critical care physicians continue to rely on standard dosing regimens for every patient, regardless of the actual clinical situation. This review outlines the pharmacokinetic and pharmacodynamic principles that underlie the need for individualized and personalized drug dosing. At present, therapeutic drug monitoring may be of help, but has major disadvantages, remains unavailable for most antibiotics and has produced mixed results. We therefore propose the AutoKinetics concept, taking decision support for antibiotic dosing back to the bedside. By direct interaction with electronic patient records, this opens the way for the use of big data for providing the right dose at the right time in each patient.

[1]  M. Levy,et al.  GUIDELINE BUNDLES ADHERENCE AND MORTALITY IN SEVERE SEPSIS AND SEPTIC SHOCK: RESULTS OF A NATIONAL PATIENT SAFETY PROGRAM IN THE NETHERLANDS , 2014, Critical care medicine.

[2]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[3]  Stephan Harbarth,et al.  Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  D. Paterson,et al.  Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. , 2010, International journal of antimicrobial agents.

[5]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[6]  J. Rello,et al.  Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients , 2014, Intensive Care Medicine.

[7]  J. Rello,et al.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  Jason A Roberts,et al.  Therapeutic drug monitoring of antimicrobials. , 2012, British journal of clinical pharmacology.

[9]  G. Martin.  Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes , 2012, Expert review of anti-infective therapy.

[10]  J. Marshall.  Why have clinical trials in sepsis failed? , 2014, Trends in molecular medicine.

[11]  J. Beney,et al.  Clinical and economic outcomes of pharmaceutical services related to antibiotic use: a literature review , 2007, Pharmacy World & Science.

[12]  A H Thomson,et al.  Cost-Effectiveness of Therapeutic Drug Monitoring: A Systematic Review , 2005, Therapeutic drug monitoring.

[13]  G. Drusano,et al.  Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia , 2009, European Respiratory Journal.

[14]  Joyce Polessi,et al.  The impact of each action in the Surviving Sepsis Campaign measures on hospital mortality of patients with severe sepsis/septic shock Impacto de cada ação dos pacotes da Surviving Sepsis Campaign na mortalidade hospitalar de pacientes portadores de sepse grave/choque séptico , 2008 .

[15]  J. Rello,et al.  Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study , 2014, Critical Care.

[16]  Brian Whiting,et al.  THERAPEUTIC DRUG MONITORING , 1982, The Lancet.

[17]  Michael N Neely,et al.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. , 2014, The Lancet. Infectious diseases.

[18]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 , 2013, Critical care medicine.

[19]  Mark A. Miller,et al.  Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  D. Angus,et al.  Epidemiology of severe sepsis , 2013, Virulence.

[21]  T. Whitehouse,et al.  Vancomycin-Associated Nephrotoxicity in the Critically Ill: A Retrospective Multivariate Regression Analysis* , 2014, Critical care medicine.